Efficiency of complete omentectomy in patients with resectable gastric cancer: a meta-analysis and systematic review

Akao Zhu†, Guang Yin†, Xinchun Liu†, Wencheng Kong, Yu Zhang, Yuqiang Shan, Rongchao Ying, Jian Zhang* and Chunhua Zhou*

Abstract

Background: We performed a meta-analysis to investigate the efficacy of complete omentectomy (CO) in patients undergoing radical gastrectomy for gastric cancer.

Methods: We conducted a literature search in PubMed, Web of Science, and the Cochrane Library databases for clinical research that compared CO with non-complete omentectomy (NCO). These articles were published prior to April 2021. Overall survival (OS) rates, relapse-free survival (RFS) rates, recurrence rates, operation times, estimates of blood loss, numbers of harvested lymph nodes, complications, and lengths of hospital stays were compared using relative risks (RRs) and weighted mean differences (WMDs). RevMan 5.3 software was used for statistical analysis.

Results: Nine studies that included 3329 patients (1960 in the CO group) and 1369 in the NCO group comprised the analysis. The meta-analysis showed that CO was associated with a decreased 3-year OS rate (RR = 0.94, 95% CI 0.90–0.98, P = 0.005) and 5-year OS rate (RR = 0.93, 95% CI 0.88–0.98, P = 0.007). However, it was not associated with the 3-year RFS rate (RR = 0.97, 95% CI 0.90–1.04, P = 0.44), 5-year RFS (RR = 0.98, 95% CI 0.90–1.06, P = 0.60), or recurrence rate (RR = 1.17, 95% CI 0.95–1.45, P = 0.15) compared to the NCO group. For surgical-related outcomes, significant heterogeneity existed between the studies. Compared to the NCO group, CO was found to be associated with significantly more estimated blood loss (WMD = 250.90, 95% CI 105.90–396.28, P = 0.0007) and less harvested lymph nodes (WMD = −3.59, 95% CI −6.88, −0.29, P = 0.03). Although, there was no significant difference in the surgical time (WMD = 15.93, 95% CI −0.21, 32.07, P = 0.05). No statistically significant differences were observed in the rates of overall complications (P = 0.79) and major complications (P = 0.90), or the lengths of hospital stays (P = 0.11) between the two groups.

Conclusions: Based on the available evidence, CO is not superior to NCO in terms of survival. CO is not recommended as a routine surgery for gastric cancer. Future well-designed high-quality RCTs are warranted.

Keywords: Gastric cancer, Omentectomy, Overall survival, Complication, Meta-analysis

Background

Gastric cancer (GC) poses a major threat to global health. It is estimated to be the fifth most commonly diagnosed cancer and the fourth leading cause of cancer-related mortality worldwide [1]. Although many treatment modalities, such as systemic chemotherapy, radiotherapy, immunotherapy, and targeted therapy have validated...
efficacy in GC, radical gastrectomy remains the mainstay of curative treatment for GC. Radical gastrectomy should be performed whenever possible [2]. However, the extent of radical gastrectomy for gastric cancer has not reached a consensus. For example, although commonly performed, the efficiency of complete omentectomy (CO) during radical gastrectomy has not yet been universally acknowledged [3–5]. The greater omentum is an apron-like fatty adipose tissue that extends from the stomach. It functions as a protective cushion and is responsible for peritoneal defenses [6]. The Japanese gastric cancer treatment guidelines recommend the removal of the greater omentum in standard gastrectomy for T3 or deeper tumors. The guidelines recommend the preservation of the omentum more than 3 cm away from the gastroepiploic artery for T1/T2 tumors [7]. To the best of our knowledge, there is only one meta-analysis that has explored the impact of omentectomy in patients with locally advanced gastric cancer [8]. This meta-analysis revealed that omentectomy had no significant impact on 5-y overall survival (OS) or 5-y recurrence-free survival (RFS). It included eight retrospective studies, including four studies in English, three studies in Japanese, and one study in Korean. It also included two studies that compared omentobursectomy and omentectomy. Moreover, since the literature search was conducted until December 2020, additional new studies have become available [9–11], including one randomized controlled trial [10]. Therefore, we designed and conducted this systematic review and meta-analysis to summarize the current evidence in the English literature on the clinical value of CO. This review was performed in terms of oncological outcomes, intraoperative safety, and postoperative recovery in GC patients undergoing gastrectomy.

Methods
This systematic review was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 statement [12]. This study was not registered.

Literature search strategy
We performed a systematic literature search in PubMed, Web of Science, and The Cochrane Library for eligible studies that investigated the efficacy of CO in patients who underwent gastrectomy for gastric cancer. The search strategy was (“omentum” OR “omentumectomy” OR “omentum preservation” OR “omentum-preserving”) AND (“gastrectomy” OR “gastrostomy”) AND (“gastric cancer” OR “gastric carcinoma”). No language restrictions were used in the search strategy. The latest search was conducted on April 17, 2021.

Study selection criteria and quality assessment
Studies that compared the outcomes of gastrectomy with CO and gastrectomy with non-CO (NCO) in patients with gastric cancer were included in the meta-analysis. The exclusion criteria were as follows: (1) non-human gastric cancer trials; (2) irretrievable data; (3) lack of comparison groups or lack of baseline data comparison; (4) evaluation of the correlation between bursectomy and outcomes in gastric cancer patients; (5) non-English articles; and (6) studies in the form of expert opinions, comments, or letters.

The quality of randomized controlled trials (RCTs) was assessed using the Cochrane Collaboration tool [13]. The quality of non-RCTs was assessed using the modified version of the Methodological Index for Non-randomized Studies (MINORS) [14]. A funnel plot analysis was performed to detect publication bias when more than ten studies were included.

Outcome measures and data extraction
The primary outcomes of this meta-analysis were survival outcomes, including recurrence rates, OS rates, and the RFS rates of each eligible trial. The secondary outcomes included evaluation of CO in terms of surgical-related outcomes (operation time, estimated blood loss, and harvested lymph nodes) and postoperative recovery outcomes (overall complications, major complications, and length of postoperative hospital stays [LOS]).

The following data were independently extracted by two reviewers (AZ and YZ): first author, year of publication, country of investigators, study period, study design, sample size, study population characteristics, follow-up period, and primary and secondary outcomes. Inconsistencies between authors were resolved by discussion and arbitrated by a third reviewer (XL).

Statistical analysis
The meta-analysis was performed using “Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014”. When the mean or the standard deviation (SD) of an endpoint was not provided, it was calculated from the reported median, range, or interquartile range (IQR) if provided [15]. Moreover, survival outcome analyses were based on the extraction of unavailable data from the Kaplan–Meier curves. For dichotomous outcomes, risk ratios (RR) and the corresponding 95% confidence intervals (CI) were calculated using the Mantel–Haenszel (MH) method. For continuous outcomes, weighted mean differences (WMD) and corresponding 95% CI were calculated using the inverse variance method. \( I^2 \) statistics were used to assess the statistical heterogeneity. \( I^2 \) values
of <25, 25–50, and >50% were considered low, moderate, and high heterogeneity, respectively. Given the heterogeneity of the tumors and patient characteristics, along with the diversity of the surgical approaches and techniques between studies, a random-effects model was used as the default for all statistical analyses. Subgroup analysis was performed for studies with a randomized or propensity score-matching (PSM) design. Sensitivity analysis was performed to evaluate the stability of the primary outcomes. The studies involved in the meta-analysis were deleted one by one to evaluate the influence of individual study data on the pooled effect estimate. Statistical significance was set at $P < 0.05$.

**Results**

**Literature search results and characteristics of the included studies**

Figure 1 presents a flowchart detailing the study selection process. The search strategy initially extracted 501 items from the searched electronic databases (208 in PubMed, 39 in Cochrane Library, and 254 in Web of Science). After carefully removing duplications, screening the titles, abstracts, and full texts according to the inclusion and exclusion criteria, nine studies were included in the systematic review and meta-analysis. These studies were utilized to assess the efficacy of CO in gastrectomy for gastric cancer [4, 9–11, 16–20].

Of the nine studies, eight were conducted in East Asia (Korea or Japan), and one was conducted in the US. Of the nine studies, one was an RCT [10] and the remaining eight were retrospective comparative studies, with four using PSM. The study period of the included studies ranged from 2000 to 2018. The number of patients in each study ranged from 37 to 1116. Overall, 3329 patients were included in the meta-analysis, with 1960 patients in the CO group and 1369 patients in the NCO group.

The RCT quality assessment showed a low risk of bias in random sequence generation, low risk of bias in allocation concealment, high risk of bias in blinding of participants and personnel, unclear risk of bias in blinding of outcome assessment, high risk of bias in incomplete outcome data, unclear bias in selective reporting, and an unclear risk of other bias. Quality assessment of studies showed that all non-RCT studies had a score of ≥17 points out of 24 points, indicating that the studies were of high quality. The detailed baseline characteristics of the nine included studies are summarized in Table 1.

**Meta-analysis of outcomes**

**Survival outcomes**

Six studies reported data on 3-year-and 5-year OS with low heterogeneities [4, 9, 11, 17, 18, 20]. The meta-analysis showed that the NCO group had a better 3-year OS rate than the CO group (RR = 0.94, 95% CI 0.90–0.98, $P = 0.005$, $I^2 = 0\%$, Fig. 2A). The NCO group also had a better 5-year OS rate than the CO group (RR = 0.93, 95% CI 0.88–0.98, $P = 0.007$, $I^2 = 5\%$, Fig. 2B).

Five studies reported data on 3-year and 5-year RFS with moderate heterogeneities [4, 11, 17, 18, 20]. The meta-analysis showed that there was neither a significant difference in the 3-year RFS rate (RR = 0.97, 95% CI 0.90–1.04, $P = 0.44$, $I^2 = 36\%$, Fig. 2C) nor in the 5-year RFS rate (RR = 0.98, 95% CI 0.90–1.06, $P = 0.60$, $I^2 = 40\%$, Fig. 2D) between the CO and NCO groups.

Six studies reported data on recurrence with low heterogeneity [4, 11, 17–20]. No statistically significant difference in recurrence rate was observed between the CO and NCO groups (RR = 1.17, 95% CI 0.95–1.45, $P = 0.15$, $I^2 = 19\%$, Fig. 2E).

**Surgical-related outcomes**

Six studies reported data on surgical time with high heterogeneity [4, 9–11, 16, 17, 19]. The meta-analysis revealed that the operation time of the CO group was longer than that of the NCO group. However, the difference was not significant (WMD = −15.93, 95% CI −0.21 to 32.07, $P = 0.05$, $I^2 = 90\%$, Fig. 3A).

Four studies reported data on estimated blood loss with high heterogeneity [4, 10, 11, 17]. The meta-analysis revealed that the CO group was associated with significantly more estimated blood loss than the NCO group (WMD = −250.90, 95% CI 105.90–396.28, $P = 0.0007$, $I^2 = 98\%$, Fig. 3B).

Two studies did not report the types of lymphadenectomy. There was heterogeneity in the types of lymphadenectomy among the remaining studies (Table 1). Nevertheless, seven studies reported data on the number of harvested lymph nodes with high heterogeneity [4, 9–11, 16, 18, 19]. The meta-analysis revealed that CO group had significantly fewer harvested lymph nodes than NCO group (WMD = −3.59, 95% CI −6.88, −0.29, $P = 0.03$, $I^2 = 84\%$, Fig. 3C).

**Postoperative recovery outcomes**

Overall and major complications were reported in 4 [9, 11, 17, 20] and five studies [4, 10, 11, 16, 20], respectively. Meta-analysis revealed that there was no significant difference in overall (RR = 0.98, 95% CI 0.84–1.14, $P = 0.79$, $I^2 = 0\%$, Fig. 4A) or major complication rates (RR = 1.04, 95% CI 0.58–1.84, $P = 0.90$, $I^2 = 62\%$, Fig. 4B) between the two groups.

Four studies mentioned the length of postoperative hospital stays with high heterogeneity [4, 9, 11, 19]. The length of hospital stays was similar between the two groups (WMD = 0.41, 95% CI −0.10 to 0.93, $P = 0.11$, $I^2 = 68\%$, Fig. 4C).
Subgroup analysis
Subgroup analyses were performed for studies with PSM or randomized designs [4, 10, 11, 17, 20]. The meta-analysis confirmed that NCO was associated with a better 3-year OS rate (RR = 0.94, 95% CI 0.89–0.98, \(P=0.01\), \(I^2 = 0\%), Fig. 5A) and a lower estimated blood loss (WMD = 250.90, 95% CI 105.90–396.28, \(P=0.0007\), \(I^2 = 98\%\), Additional file 1: Fig. S1). However, it was not associated with the other remaining outcomes (Fig. 5, Additional files 1 and 2: Figs. S1 and S2).
Table 1 Characteristics of the included studies

| Authors          | Country | Study design | Group | Sample size | Age (years) | Sex (M/F) | BMI (kg/m²) | Surgical approach (Open/MIS) | Procedure (DG/TG) | Pathological T stage | Lymphadenectomy extent | Scoreb |
|------------------|---------|--------------|-------|-------------|-------------|-----------|-------------|-------------------------------|-------------------|---------------------|------------------------|--------|
| Seo et al. 2021  | Korea   | Retrospective | CO    | 225         | 59 (49–70) | 131/94    | 23.5 (21.1–25.6) | 60/165                        | T3/T4a 100/125    | D1 + /D2: 25/200   | 20/24                  |        |
|                  |         |              | NCO   | 225         | 56 (49–67) | 137/88    | 22.9 (21.0–24.9) | 69/156                        | T3/T4a 111/114    | D1 + /D2: 22/203  |                        |        |
|                   |         |              |       | 122         | 71 (30–90) | 89/33     | 22.4 (14.8–31.8) | 122/0                         | 73/49            | D2: 122             |                        |        |
|                   |         |              | NCO   | 125         | 74 (45–89) | 89/36     | 22.2 (14.5–32.1) | 125/0                         | 81/44            | D2: 125             |                        |        |
| Murakami et al. 2021 | Japan  | Prospective RCT | CO    | 122         | 71 (30–90) | 89/33     | 22.4 (14.8–31.8) | 122/0                         | 73/49            | D2: 122             |                        |        |
|                   |         |              | NCO   | 125         | 74 (45–89) | 89/36     | 22.2 (14.5–32.1) | 125/0                         | 81/44            | D2: 125             |                        |        |
| Sakimura et al. 2020 | Japan  | Retrospective | CO    | 70          | 65.0 (37–90) | 46/22     | 22.2 (15.8–30.3) | 41/29                         | 45/25            | D1 + /D2 or more: 9/61 | 20/24                 |        |
|                   |         |              | NCO   | 70          | 66.5 (42–94) | 48/22     | 22.4 (16.4–32.6) | 25/45                         | 44/26            | D1 + /D2 or more: 14/56 | 22/24                 |        |
| Rì et al. 2020    | Japan   | Retrospective | CO    | 263         | 66.7 ± 11.0 | 176/87  | 22.4 ± 3.6   | 263/0                         | 156/107          | T1-2/T3-4: 47/216 | ≤ D1/D1 + /D2 or more: 11/146/106 |        |
|                   |         |              | NCO   | 263         | 66.7 ± 12.9 | 181/82  | 22.5 ± 3.4   | 263/0                         | 151/112          | T1-2/T3-4: 48/215 | ≤ D1/D1 + /D2 or more: 8/146/109 |        |
| Young et al. 2020 | USA     | Retrospective | CO    | 90          | 69.5 (62–77) | 62/28  | 27.4 ± 6.1   | NA                           | T2/T3 or T4: 41 | NA                  |                        | 18/24 |
|                   |         |              | NCO   | 381         | 68.5 (58–76) | 217/164 | 26.2 ± 5.3   | NA                           | T2/T3 or T4: 184 | NA                  |                        |        |
| Kim et al. 2014   | Korea   | Retrospective | CO    | 80          | 60.9 ± 11.2 | 56/24  | NA           | 0/80                         | 61/19            | D1 + /D2: 2.7/8 | 19/24                  |        |
|                   |         |              | NCO   | 66          | 62.2 ± 11.0 | 50/16  | NA           | 0/66                         | 24/12            | D1 + /D2: 5.6    |                        |        |
| Hasegawa et al. 2013 | Japan  | Retrospective | CO    | 98          | 69.0 (40–91) | 72/26  | NA           | 98/0                         | 52/46            | D1 + /D2 or more: 12/86 | 17/24                 |        |
|                   |         |              | NCO   | 98          | 68.7 (45–91) | 72/26  | NA           | 84/14                        | 61/37            | D1 + /D2 or more: 13/85 | 17/24                 |        |
| Kim et al. 2011   | Korea   | Retrospective | CO    | 20          | 58.2 ± 9.5 | 17/3   | 23.3 ± 2.3   | 20/0                         | 20/0             | ≤ D1 + /B > D2: 13/7 | 17/24                 |        |
|                   |         |              | NCO   | 17          | 58.6 ± 10.1 | 11/6   | 23.6 ± 2.7   | 17/0                         | 17/0             | ≤ D1 + /B > D2: 15/2 | 17/24                 |        |
| Ha et al. 2008    | Korea   | Retrospective | CO    | 992         | 57.0 ± 113  | 681/311 | NA           | NA                           | TA: 75, Others: 917 | early gastric cancer | early gastric cancer | NA      |
|                   |         |              | NCO   | 124         | 56.3 ± 113  | 87/37  | NA           | NA                           | TA: 25, Others: 99 | NA                  |                        |        |

CO, complete omentectomy; NCO, non-complete omentectomy; BMI, body mass index; DG, distal gastrectomy; TG, total gastrectomy; STG: subtotal gastrectomy; PSM, propensity score matching; RCT, randomized controlled study; MIS, minimally invasive surgery; NA, not available

aData are shown as median (range); bMINORS score for non-RCTs

Fig. 2 Meta-analysis comparing A 3-year overall survival rate, B 5-year overall survival rate, C 3-year relapse-free survival rate, D 5-year relapse-free survival, E recurrence rate. CO, complete omentectomy; NCO, non-complete omentectomy.
To perform sensitivity analysis, studies were excluded in turn to assess whether individual studies influenced the pooled RRs of the outcomes. For every meta-analysis of the primary outcomes and postoperative recovery outcomes, the pooled RRs were similar after each study was excluded. This verified the stability of the meta-analysis. For every meta-analysis of the operation-related outcomes, the pooled RRs were significantly changed after the selective studies were excluded. Publication bias was not assessed as fewer than ten studies were included in the meta-analysis.

**Discussion**

This meta-analysis systematically investigated the effects of CO on radical gastrectomy for gastric cancer. Our study showed that CO did not improve survival compared to NCO. In contrast, CO was associated with significantly worse 3-year and 5-year OS. Although, there was no significant difference in the 3-year and 5-year RFS or recurrence rates. Moreover, CO was associated with more estimated blood loss and fewer harvested lymph nodes. There was no statistically significant difference in the postoperative recovery, in terms of overall complications, major complications, and LOS between the CO and NCO groups.

D2 lymphadenectomy represents the gold standard for treating advanced gastric cancer [21]. Laparoscopic gastrectomy is widely accepted as an alternative to open gastrectomy [22–24]. However, the extent of resection remains to be determined. Previously, bursectomy, which removes the anterior membrane of the transverse colon and the peritoneal lining covering the pancreas with a total omentectomy, has been recommended as an essential part of complete radical gastrectomy [25]. However, this has been challenged. Recently, Xiong et al. performed a meta-analysis of 15 studies with 4858 patients to investigate the safety and efficiency of bursectomy during radical gastrectomy for patients with gastric cancer [26]. They found that although bursectomy was associated with a prolonged operative time and more intraoperative blood loss, it was not superior to non-bursectomy. This was in terms of oncological outcomes, such as the number of dissected lymph nodes, survival rates, and
bursectomy should not be a routine surgery for resectable cT3 or cT4a gastric cancer. This was supported by a high-quality RCT [27].

The aim of CO was similar to that of bursectomy, with the removal of concurrent micrometastases and potential sites of recurrence. However, the prevalence and significance of concurrent omental micrometastases remains controversial. One study found that 10% of gastrectomy patients harbored tumor deposits or lymph node metastases in the greater omentum [5]. Moreover, factors predicting omental tumor involvement could not be identified. Therefore, omentectomy should be the standard gastrectomy for patients with gastric cancer [5]. Meanwhile, other studies found that metastases in the greater omentum occurred in only 1.6% of GC patients who underwent gastrectomy [3, 28]. These were correlated significantly with non-radical features and advanced disease, indicating stage IV disease and a poor prognosis [11, 29]. In another study, Metwally et al. compared the survival of gastric cancer patients with/without tumor infiltration in the omentum. They found that omental infiltration was not associated with overall or disease-free survival [30].

In this meta-analysis, the included studies consistently found no significant survival benefit for CO. Moreover, a meta-analysis of all included studies found that CO is associated with a decreased 3-year OS and 5-year OS. Subsequent subgroup analysis for randomized or PSM studies confirmed that CO was associated with a decreased 3-year OS, but not with 5-year OS. This is in line with the findings of Ishizuka et al. [8]. In addition, NCO is less challenging, with less estimated blood loss. Although one study by Olmi et al. [31] found that omentum preservation was associated with a lower incidence of recurrence and a lower incidence of complications than in patients with omentectomy, these effects were not observed in this meta-analysis. However, it is of note that omental preservation may have specific complications, such as omental infarction and trocar herniation. This may cause abdominal pain [32, 33]. This meta-analysis also found that NCO was associated with a higher LN yield, which is contrary to intuition. One potential reason might be that even in omentum preservation, lymph

---

![Fig. 4 Meta-analysis comparing overall complications, major complications, length of postoperative hospital stay. CO, complete omentectomy; NCO, non-complete omentectomy](image-url)
nodes along the gastroepiploic arcade could be dissected completely [11]. However, a smaller omental specimen might compel the pathologist to check the lymph nodes more cautiously. This would result in a higher LN yield. This is more likely to be associated with different types of lymphadenectomies between studies.

This study had several limitations. First, the number of eligible studies was limited and some outcomes

Fig. 5 Subgroup meta-analysis for studies with PSM or randomized designs comparing A 3-year overall survival rate, B 5-year overall survival rate, C 3-year relapse-free survival rate, D 5-year relapse-free survival, E recurrence rate. CO, complete omentectomy; NCO, non-complete omentectomy
of interest were not reported in all eligible studies. Furthermore, some outcomes suffer from moderate to high heterogeneity between the two groups. The types of lymphadenectomy and the harvested lymph nodes are examples, thus decreasing the power of this meta-analysis. Second, most included studies were from Japan and Korea, which may limit the application of the results in Western populations. Third, although it is likely that omentectomy might be useful for patients with T3/4 stage gastric cancers, it was impossible to perform a subgroup analysis with few studies focusing on the effect of CO in this subgroup of patients. Despite these limitations, the results of the present meta-analysis challenged the justification for CO. Omentum preservation could be a better choice than CO with regard to oncological outcomes and surgical effort.

Conclusions
In conclusion, CO did not benefit survival, operative, or recovery outcomes when compared to NCO. Based on the available evidence, CO is not recommended as a standard procedure for resectable gastric cancer. Future well-designed, high-quality RCTs are warranted to clarify the efficacy of CO in radical gastrectomy, especially in cT3 or cT4 gastric cancer.

Abbreviations
GC: Gastric cancer; CO: Complete omentectomy; OS: Overall survival; RFS: Relapse-free survival; PRISMA: Preferred Reporting Items for Systematic Reviews and Meta-Analyses; NCO: Non-complete omentectomy; RCT: Randomized controlled trial; MINORS: Methodological Index for Non-randomized Studies; LOS: Postoperative hospital stays; SD: Standard deviation; RR: Risk ratios; MH: Mantel–Haenszel; WMD: Weighted mean differences; CI: Confidence intervals; PSM: Propensity score-matching.

Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s12876-021-01921-3.

Additional file 1. Fig. S1. Subgroup meta-analysis for studies with PSM or randomized designs comparing A operation time, B estimated blood loss, C harvested lymph nodes; CO, complete omentectomy; NCO, non-complete omentectomy.

Additional file 2. Fig. S2. Subgroup meta-analysis for studies with PSM or randomized designs comparing A overall complications, B major complications, C length of postoperative hospital stay; CO, complete omentectomy; NCO, non-complete omentectomy.

Acknowledgements
The authors are grateful to the authors of the included studies and the enrolled patients.

Authors’ contributions
CZ and JZ had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Study conception and design: AZ, YZ, WK, and CZ. Acquisition of data: AZ, YZ, and XL. Analysis and interpretation of data: all authors. Drafting of the manuscript: AZ and YZ. Critical revision of the manuscript for important intellectual content: all authors. Statistical analysis: ZL, XL, GY, and XL. Obtaining funding: AZ and JZ. Supervision: YS and RY. All authors contributed to the article and approved the submitted version. All authors read and approved the final manuscript.

Funding
This work was supported by Zhejiang Traditional Chinese Medicine Administration (2021ZAK112) and Natural Science Foundation of Zhejiang Province (LQ20H160017).

Availability of data and materials
The original data used in the study are all included in the article, further inquiries can be directed to the corresponding author.

Declarations
Ethics approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1Department of Gastrointestinal Surgery, Affiliated Hangzhou First People’s Hospital, Zhejiang University School of Medicine, Hangzhou 31006, China.
2Department of Surgical Oncology, Affiliated Hangzhou First People’s Hospital, Zhejiang University School of Medicine, Hangzhou 31006, China.

Received: 5 June 2021 Accepted: 24 August 2021
Published online: 14 September 2021

References
1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209.
2. Joshi SS, Badgwell BD. Current treatment and recent progress in gastric cancer. CA Cancer J Clin. 2021;71:264.
3. Jongerius EJ, Boerma D, Seldennik JA, Meijer SL, Scheckers JJ, Smeets F, Lagarde SM, Balague Ponz O, van Berge Henegouwen MI, van Sandick JW, et al. Role of omentectomy as part of radical surgery for gastric cancer. Br J Surg. 2016;103(11):1497–503.
4. Ri M, Nunobe S, Honda M, Akimoto E, Kinoshita T, Hori S, Aizawa M, Yabusaki H, Isobe Y, Kawakubo H, et al. Gastrectomy with or without omentectomy for cT3-4 gastric cancer: a multicentre cohort study. Br J Surg. 2020;107(12):1640–7.
5. Haverkamp L, Brenchman HJ, Ruurda JP, Ten Kate FJ, van Hillegersberg R. The oncological value of omentectomy in gastrectomy for cancer. J Gastrointest Surg Off J Soc Surg the Alimentary Tract. 2016;20(5):885–90.
6. Platell C, Cooper D, Papadimitrou JM, Hall JC. The omentum. World J Gastroenterol. 2000;6(2):169–76.
7. Japanese Gastric Cancer A: Japanese gastric cancer treatment guidelines 2018 (5th edition). Gastric Cancer 2021;24(1), 1–21.
8. Ishizu M, Shibuya N, Takagi K, Hachiya H, Tago K, Matsumoto T, Shimizu T, Aoki T, Kubota K. Omentectomy does not affect the postoperative outcome of patients with locally advanced gastric cancer: a systematic review and meta-analysis. J Surg Res. 2021;264:287–95.
9. Young S, DiForza LO, Ahuja A, Kimm L, Papenfuss C, O’Connor V, Dehal P. Performing omentectomy during gastrectomy does not improve survival: a multi-center analysis of 471 patients with gastric adenocarcinoma. J Gastrointest Surg Off J Soc Surg the Alimentary Tract. 2020;24(1):2656–8.
10. Murakami H, Yamada T, Taguri M, Hasegawa S, Yamanaka T, Rino Y, Mushiake H, Oshima T, Matsukawa H, Tani K, et al. Short-term outcomes from a randomized screening Phase II non-inferiority trial comparing
omentectomy and omentum preservation for locally advanced gastric cancer: the TOP-G Trial. World J Surg. 2021;45:1863.

11. Seo WJ, Choi S, Roh CK, Cho M, Kim YM, Kim HI, Hyung WJ. Omentum preservation as an oncologically comparable and surgically superior alternative to total omentectomy during radical gastrectomy for T3–T4 gastric cancer. Surgery. 2021;170:610.

12. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseser T, Tetzlaff JM, Akl EA, Brennan SE, et al. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. Int J Surg. 2021;88:105908.

13. Higgins JP, Altman DG, Gotzsche PC, Juni P, Moher D, Oxman AD, Savovic J, Schulz KF, Weeks L, Sterne JA, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928.

14. Slim K, Nini E, Forester D, Kwiatkowski F, Panis Y, Chipponi J. Methodological index for non-randomized studies (minors): development and validation of a new instrument. ANZ J Surg. 2003;73(9):712–6.

15. Wan X, Wang W, Liu J, Tong T. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Med Res Methodol. 2014;14:135.

16. Ha TK, An JY, Youn HG, Noh JH, Sohn TS, Kim S. Omentum-preserving gastrectomy for early gastric cancer. World J Surg. 2008;32(8):1703–8.

17. Hasegawa S, Kunisaki C, Ono H, Oshima T, Fujii S, Taguri M, Motta S, Sato T, Yamada R, Yukawa N, et al. Omentum-preserving gastrectomy for advanced gastric cancer: a propensity-matched retrospective cohort study. Gastric Cancer. 2013;16(3):383–8.

18. Kim DJ, Lee JH, Kim W. A comparison of total versus partial omentectomy for advanced gastric cancer in laparoscopic gastrectomy. World J Surg Oncol. 2014;12:64.

19. Kim MC, Kim KH, Jung GJ, Rattner DW. Comparative study of complete and partial omentectomy in radical subtotal gastrectomy for early gastric cancer. Yonsei Med J. 2011;52(6):961–6.

20. Sakimura Y, Inaki N, Tsuji T, Kadoya S, Bando H. Long-term outcomes of bursectomy and omentum-preserving gastrectomy with gastric cancer: a propensity score-matching analysis. Surg Endosc. 2019;33(1):58–70.

21. Liu F, Huang C, Xu Z, Su X, Zhao G, Ye J, Du X, Huang H, Hu J, Li G, et al. Morbidity and mortality of laparoscopic omentectomy over open total gastrectomy for clinical stage i gastric cancer: The CLASS02 Multicenter Randomized Clinical Trial. JAMA Oncol. 2020;6(10):1590–7.

22. Oh Y, Kim MS, Lee YT, Lee CM, Kim JH, Park S. Laparoscopic total gastrectomy as a valid procedure to treat gastric cancer option both in early and advanced stage: a systematic review and meta-analysis. Eur J Surg Oncol. 2020;46(1):33–43.

23. Marano L, Polom K, Bartoli A, Spaziani A, De Luca R, Lorenzon L, Di Martino N, Marelli D, Roviello F, Castagnoli G. Oncologic effectiveness and safety of bursectomy in patients with advanced gastric cancer: a systematic review and updated meta-analysis. J Invest Surg. 2018;31(6):529–38.

24. Xiong B, Ma L, Huang W, Cheng Y, Luo H, Wang K. Efficiency of bursectomy in patients with resectable gastric cancer: an updated meta-analysis. Eur J Surg Oncol. 2019;45(8):1483–92.

25. Kurokawa Y, Doki Y, Mizusawa J, Terashima M, Katai H, Yoshikawa T, Kimura Y, Takiguchi S, Nishida Y, Fukushima N, et al. Bursectomy versus omentectomy alone for resectable gastric cancer (JCOG1001): a phase 3, open-label, randomised controlled trial. Lancet Gastroenterol Hepatol. 2018;3(7):460–8.

26. Barchi LC, Ramos M, Dias AR, Yagi OK, Ribeiro-Junior U, Zilberstein B, Cecconello I. Total Omentectomy in gastric cancer surgery: is it always necessary? Brazil Arch Digest Surg. 2019;32(1):e1425.

27. Fujitani K, Yang HK, Mizusawa J, Kim YW, Terashima M, Han SU, Iwasaki Y, Hyung WJ, Takagane A, Park DJ, et al. Gastrectomy plus chemotherapy versus chemoradiotherapy as an open surgical approach in resectable gastric cancer: a single-center experience (JCOG9915). J Gastrointest Cancer. 2010;41(2):100–4.

28. Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews and meta-analyses. JMIR Res Protoc. 2020;9(11):e23722.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.